News
FDA Advisors Recommend AstraZeneca and Sanofi Antibody for Protecting Babies from RSV
(CTN News) – Among the top causes of newborn hospitalization is an (RSV) respiratory syncytial virus, and a panel of independent advisors to the FDA unanimously recommended Thursday that the antibody nirsevimab be licensed to protect infants from the virus.
Nirsevimab Could Be the First Medical Intervention for RSV Protection in the US
If nirsevimab receives FDA approval, it will be the first medical intervention in the United States capable of protecting all infants from RSV. The FDA is likely to reach a final decision on nirsevimab in the third quarter, though it is under no obligation to do so.
AstraZeneca produces a monoclonal antibody called nirsevimab. Sanofi would be responsible for marketing the drug.

The panel unanimously (21) agreed to recommend acceptance.
Separately, the advisors voted to use nirsevimab in children younger than 2 susceptible to RSV during their second RSV season. The final tally was 19-2.
Scientists estimate that RSV kills about 100 American infants annually.
Hospitalized infants with RSV frequently need respiratory support from a ventilator, oxygen therapy, and intravenous fluids.
The virus poses a serious risk to public health. There were calls for the Biden administration to declare a public health emergency last year after an outbreak of respiratory syncytial virus swamped children’s hospitals.
Hospitals already feel the strain when respiratory syncytial virus (RSV) spreads simultaneously as influenza and Covid-19.
Another anti-RSV monoclonal antibody, named palivizumab, has been developed. However, this antibody is reserved for extremely vulnerable newborns born prematurely or with preexisting lung or heart abnormalities. In addition, palivizumab needs to be injected once a month.
In contrast, nirsevimab would be given to healthy infants, who account for most hospitalizations. The single-dose format also simplifies administration.
Since nirsevimab is a monoclonal antibody, it cannot be classified as a vaccination.
Since nirsevimab is a medication, it is uncertain if the government Vaccines for Children program will cover the cost of providing the antibody to uninsured and underinsured children.
Canada, Europe, and the UK have all given their stamps of approval to nirsevimab.
The expert on infectious disease drugs, Nimish Patel, said nirsevimab worked “extraordinarily well” in both premature and full-term infants.
“The once-seasonal dosing is a huge advance and this is probably the closest thing to an RSV vaccine that we have and it really moves the field forward,” said Patel, who is on the FDA committee and a professor of clinical pharmacy at the University of California, San Diego.
The FDA found that nirsevimab reduced the risk of hospitalization by 78% and reduced the risk of lower respiratory tract infections by 75%.
The FDA estimated more modestly that the antibody would be 48% effective against serious lower respiratory tract infections. This estimate was based on the hypothesis that individuals missing health outcome data suffered from a medically significant case of lower respiratory tract infection.
A single injection of nirsevimab, the amount determined by the infant’s weight, is required. For the first RSV season, infants weighing less than 5 kilograms would get an injection of 50 mg, while those weighing 5 kilograms or more would get an injection of 100 mg.
A 200 mg injection of nirsevimab would be given to children younger than 2 years old who continue to be at risk for severe RSV in their second season.
In their evaluation of nirsevimab, the FDA found no evidence of any safety issues.
Hypersensitivity responses, including severe allergic reactions and skin rashes, have been linked to various monoclonal antibodies.
Nirsevimab studies showed a low rate of skin rash and hypersensitivity reactions in newborns. However, the FDA could not uncover any incidences of significant adverse reactions.
However, an FDA official, Dr. Melissa Baylor, has indicated that these side effects will likely occur if nirsevimab is given the green light.
In the trials of nirsevimab, twelve newborns perished. The FDA found no evidence that the antibody caused any of these deaths.
Eight people lost their lives; four to heart disease, two to gastroenteritis, two to what is presumably SIDS, one to a tumor, one to Covid, one to a skull fracture, and one to pneumonia.
According to Baylor, “most deaths were due to an underlying disease.” “Nirsevimab did not appear to be involved in any of the deaths.”
Due to previous setbacks, safety concerns have been prioritized during RSV vaccine research. In the 1960s, researchers attempted to create a vaccine using an inactivated virus; however, this shot worsened RSV sickness in some children when they received their first natural infection, and it was ultimately responsible for the deaths of two infants.
Unanswered Questions and Future Considerations for Nirsevimab and RSV Vaccines
According to AstraZeneca’s head of patient safety Manish Shroff, “Safety is of utmost importance,” and the company will be careful to check on the safety of nirsevimab through a massive worldwide monitoring system.
According to Baylor, it is also unclear how nirsevimab would react with experimental vaccines designed to safeguard a developing fetus by having the mother receive an injection.
The safety and efficacy of administering nirsevimab to infants whose moms have received these RSV vaccines is unknown, Baylor noted.
In May, the FDA’s advisory committee gave their stamp of approval to Pfizer’s RSV vaccination for pregnant women. In August, the FDA is likely to rule on Pfizer’s injection.
News
Google’s Search Dominance Is Unwinding, But Still Accounting 48% Search Revenue
Google is so closely associated with its key product that its name is a verb that signifies “search.” However, Google’s dominance in that sector is dwindling.
According to eMarketer, Google will lose control of the US search industry for the first time in decades next year.
Google will remain the dominant search player, accounting for 48% of American search advertising revenue. And, remarkably, Google is still increasing its sales in the field, despite being the dominating player in search since the early days of the George W. Bush administration. However, Amazon is growing at a quicker rate.
Google’s Search Dominance Is Unwinding
Amazon will hold over a quarter of US search ad dollars next year, rising to 27% by 2026, while Google will fall even more, according to eMarketer.
The Wall Street Journal was first to report on the forecast.
Lest you think you’ll have to switch to Bing or Yahoo, this isn’t the end of Google or anything really near.
Google is the fourth-most valued public firm in the world. Its market worth is $2.1 trillion, trailing just Apple, Microsoft, and the AI chip darling Nvidia. It also maintains its dominance in other industries, such as display advertisements, where it dominates alongside Facebook’s parent firm Meta, and video ads on YouTube.
To put those “other” firms in context, each is worth more than Delta Air Lines’ total market value. So, yeah, Google is not going anywhere.
Nonetheless, Google faces numerous dangers to its operations, particularly from antitrust regulators.
On Monday, a federal judge in San Francisco ruled that Google must open up its Google Play Store to competitors, dealing a significant blow to the firm in its long-running battle with Fortnite creator Epic Games. Google announced that it would appeal the verdict.
In August, a federal judge ruled that Google has an illegal monopoly on search. That verdict could lead to the dissolution of the company’s search operation. Another antitrust lawsuit filed last month accuses Google of abusing its dominance in the online advertising business.
Meanwhile, European regulators have compelled Google to follow tough new standards, which have resulted in multiple $1 billion-plus fines.

Pixa Bay
Google’s Search Dominance Is Unwinding
On top of that, the marketplace is becoming more difficult on its own.
TikTok, the fastest-growing social network, is expanding into the search market. And Amazon has accomplished something few other digital titans have done to date: it has established a habit.
When you want to buy anything, you usually go to Amazon, not Google. Amazon then buys adverts to push companies’ products to the top of your search results, increasing sales and earning Amazon a greater portion of the revenue. According to eMarketer, it is expected to generate $27.8 billion in search revenue in the United States next year, trailing only Google’s $62.9 billion total.
And then there’s AI, the technology that (supposedly) will change everything.
Why search in stilted language for “kendall jenner why bad bunny breakup” or “police moving violation driver rights no stop sign” when you can just ask OpenAI’s ChatGPT, “What’s going on with Kendall Jenner and Bad Bunny?” in “I need help fighting a moving violation involving a stop sign that wasn’t visible.” Google is working on exactly this technology with its Gemini product, but its success is far from guaranteed, especially with Apple collaborating with OpenAI and other businesses rapidly joining the market.
A Google spokeswoman referred to a blog post from last week in which the company unveiled ads in its AI overviews (the AI-generated text that appears at the top of search results). It’s Google’s way of expressing its ability to profit on a changing marketplace while retaining its business, even as its consumers steadily transition to ask-and-answer AI and away from search.

Google has long used a single catchphrase to defend itself against opponents who claim it is a monopoly abusing its power: competition is only a click away. Until recently, that seemed comically obtuse. Really? We are going to switch to Bing? Or Duck Duck Go? Give me a break.
But today, it feels more like reality.
Google is in no danger of disappearing. However, every highly dominating company faces some type of reckoning over time. GE, a Dow mainstay for more than a century, was broken up last year and is now a shell of its previous dominance. Sears declared bankruptcy in 2022 and is virtually out of business. US Steel, long the foundation of American manufacturing, is attempting to sell itself to a Japanese corporation.
SOURCE | CNN
News
2024 | Supreme Court Won’t Hear Appeal From Elon Musk’s X Platform Over Warrant In Trump Case
Washington — Trump Media, The Supreme Court announced Monday that it will not hear an appeal from social media platform X about a search warrant acquired by prosecutors in the election meddling case against former President Donald Trump.
The justices did not explain their rationale, and there were no recorded dissents.
The firm, which was known as Twitter before being purchased by billionaire Elon Musk, claims a nondisclosure order that prevented it from informing Trump about the warrant obtained by special counsel Jack Smith’s team violated its First Amendment rights.
The business also claims Trump should have had an opportunity to exercise executive privilege. If not reined in, the government may employ similar tactics to intercept additional privileged communications, their lawyers contended.
Supreme Court Won’t Hear Appeal From Elon Musk’s X Platform Over Warrant In Trump Case
Two neutral electronic privacy groups also joined in, urging the high court to hear the case on First Amendment grounds.
Prosecutors, however, claim that the corporation never shown that Trump utilized the account for official purposes, therefore executive privilege is not a problem. A lower court also determined that informing Trump could have compromised the current probe.

Trump utilized his Twitter account in the weeks preceding up to his supporters’ attack on the Capitol on January 6, 2021, to spread false assertions about the election, which prosecutors claim were intended to create doubt in the democratic process.
The indictment describes how Trump used his Twitter account to encourage his followers to travel to Washington on Jan. 6, pressuring Vice President Mike Pence to reject the certification, and falsely claiming that the Capitol crowd, which battered police officers and destroyed glass, was peaceful.
Supreme Court Won’t Hear Appeal From Elon Musk’s X Platform Over Warrant In Trump Case
That case is now moving forward following the Supreme Court’s verdict in July, which granted Trump full immunity from criminal prosecution as a former president.
The warrant arrived at Twitter amid quick changes implemented by Musk, who bought the company in 2022 and has since cut off most of its workforce, including those dedicated to combating disinformation and hate speech.
SOURCE | AP
News
The Supreme Court Turns Down Biden’s Government Appeal in a Texas Emergency Abortion Matter.
(VOR News) – A ruling that prohibits emergency abortions that contravene the Supreme Court law in the state of Texas, which has one of the most stringent abortion restrictions in the country, has been upheld by the Supreme Court of the United States. The United States Supreme Court upheld this decision.
The justices did not provide any specifics regarding the underlying reasons for their decision to uphold an order from a lower court that declared hospitals cannot be legally obligated to administer abortions if doing so would violate the law in the state of Texas.
Institutions are not required to perform abortions, as stipulated in the decree. The common populace did not investigate any opposing viewpoints. The decision was made just weeks before a presidential election that brought abortion to the forefront of the political agenda.
This decision follows the 2022 Supreme Court ruling that ended abortion nationwide.
In response to a request from the administration of Vice President Joe Biden to overturn the lower court’s decision, the justices expressed their disapproval.
The government contends that hospitals are obligated to perform abortions in compliance with federal legislation when the health or life of an expectant patient is in an exceedingly precarious condition.
This is the case in regions where the procedure is prohibited. The difficulty hospitals in Texas and other states are experiencing in determining whether or not routine care could be in violation of stringent state laws that prohibit abortion has resulted in an increase in the number of complaints concerning pregnant women who are experiencing medical distress being turned away from emergency rooms.
The administration cited the Supreme Court’s ruling in a case that bore a striking resemblance to the one that was presented to it in Idaho at the beginning of the year. The justices took a limited decision in that case to allow the continuation of emergency abortions without interruption while a lawsuit was still being heard.
In contrast, Texas has been a vocal proponent of the injunction’s continued enforcement. Texas has argued that its circumstances are distinct from those of Idaho, as the state does have an exemption for situations that pose a significant hazard to the health of an expectant patient.
According to the state, the discrepancy is the result of this exemption. The state of Idaho had a provision that safeguarded a woman’s life when the issue was first broached; however, it did not include protection for her health.
Certified medical practitioners are not obligated to wait until a woman’s life is in imminent peril before they are legally permitted to perform an abortion, as determined by the state supreme court.
The state of Texas highlighted this to the Supreme Court.
Nevertheless, medical professionals have criticized the Texas statute as being perilously ambiguous, and a medical board has declined to provide a list of all the disorders that are eligible for an exception. Furthermore, the statute has been criticized for its hazardous ambiguity.
For an extended period, termination of pregnancies has been a standard procedure in medical treatment for individuals who have been experiencing significant issues. It is implemented in this manner to prevent catastrophic outcomes, such as sepsis, organ failure, and other severe scenarios.
Nevertheless, medical professionals and hospitals in Texas and other states with strict abortion laws have noted that it is uncertain whether or not these terminations could be in violation of abortion prohibitions that include the possibility of a prison sentence. This is the case in regions where abortion prohibitions are exceedingly restrictive.
Following the Supreme Court’s decision to overturn Roe v. Wade, which resulted in restrictions on the rights of women to have abortions in several Republican-ruled states, the Texas case was revisited in 2022.
As per the orders that were disclosed by the administration of Vice President Joe Biden, hospitals are still required to provide abortions in cases that are classified as dire emergency.
As stipulated in a piece of health care legislation, the majority of hospitals are obligated to provide medical assistance to patients who are experiencing medical distress. This is in accordance with the law.
The state of Texas maintained that hospitals should not be obligated to provide abortions throughout the litigation, as doing so would violate the state’s constitutional prohibition on abortions. In its January judgment, the 5th United States Circuit Court of Appeals concurred with the state and acknowledged that the administration had exceeded its authority.
SOURCE: AP
SEE ALSO:
Could Last-Minute Surprises Derail Kamala Harris’ Campaign? “Nostradamus” Explains the US Poll.
-
News4 years agoLet’s Know About Ultra High Net Worth Individual
-
Entertainment2 years ago
Mabelle Prior: The Voice of Hope, Resilience, and Diversity Inspiring Generations
-
News11 years ago
Enviromental Groups Tell Mekong Leaders Lao Dam Evaluation Process Flawed
-
Health4 years agoHow Much Ivermectin Should You Take?
-
Tech3 years agoTop Forex Brokers of 2023: Reviews and Analysis for Successful Trading
-
Lifestyles3 years agoAries Soulmate Signs
-
Entertainment3 years agoWhat Should I Do If Disney Plus Keeps Logging Me Out of TV?
-
Health3 years agoCan I Buy Ivermectin Without A Prescription in the USA?


